Floatz logo

ik-175

Urothelial Neoplasm

Ikena OncologyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Urothelial Neoplasm cohort.

Asset / SponsorPhaseRating
OC-001
Ocellaris Pharma, Inc.
Phase 1/2CCC
Nivolumab
Ikena Oncology
Phase 1CC
Avelumab
Ocellaris Pharma, Inc.
Phase 1/2CC

Same molecule, other indications

ik-175 is also rated in:

Bladder Urothelial CarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
urinary bladder disorderDormant
CC
Indicative ·
47 / 100
View asset →
urinary bladder cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →